The DEA’s New Cannabis Registration System May Matter More Than Legalization Headlines
The DEA’s new cannabis registration system may quietly reshape American cannabinoid medicine. This policy shift could influence research, taxation, institutional acceptance, and physician participation far beyond the headlines. Here is what clinicians…
What the 2026 DOJ Rescheduling Order Means in Practice
On April 23, 2026, the U.S. DOJ moved state-licensed medical cannabis to Schedule III, the first federal acknowledgment of accepted medical value in 55 years. Dr. Caplan breaks down what actually changed for patients, physicians, and the research…
‘A big step forward’: Medical marijuana reclassified as less dangerous, recreational growers …
The DEA’s decision to have medical marijuana reclassified marks a significant policy shift. Medical marijuana reclassified from Schedule I to Schedule III acknowledges its accepted medical use. This change may improve research and reduce regulatory…
DEA Reschedules Cannabis to Schedule II: What It Means
The DEA cannabis schedule II reclassification marks a pivotal shift in federal drug policy. This change removes longstanding barriers to rigorous clinical research on medical marijuana. It opens new pathways for evidence-based studies and federal-state…
Imminent Cannabis Rescheduling: What Schedule III Means for Research
The cannabis schedule III regulatory impact is poised to transform clinical research and patient access. A federal decision to reschedule cannabis from Schedule I to Schedule III is imminent. This change could enable more standardized clinical trials and…
Cannabis Rescheduling Could Happen Today. Don’t Call It Legalization. | High Times
Cannabis rescheduling news highlights a potential shift from Schedule I to Schedule III, impacting medical cannabis research and clinical practice. This change could reduce regulatory barriers and enable evidence-based treatment protocols. Patients and…
US System For Classifying Marijuana And Other Drugs Does ‘Immense Damage,’ Former DEA Official Says
The controlled substances act scheduling system critically affects marijuana research and patient access. Former DEA officials highlight how this system creates barriers to clinical practice. Understanding these impacts is essential for anticipating…
Regulatory Digest: DEA Enforcement & Controlled Substances March 2026
This regulatory digest covers DEA enforcement controlled substances updates relevant to cannabis and synthetic cannabinoid importation. The March 2026 notices highlight scheduling changes and import restrictions. Clinicians should stay informed about…